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Background: Morquio A syndrome is an autosomal recessive lysosomal storage disease often resulting in life-
threatening complications. Early recognition and proficient diagnosis is imperative to facilitate prompt treatment
and prevention of clinical complications.
Methods: Experts in Asia Pacific reviewed medical records focusing on presenting signs and symptoms leading to
a diagnosis of Morquio A syndrome.
Results: Eighteen patients (77% female) had a mean (median; min, max) age of 77.1 (42.0; 0.0, 540.0) months at
symptom onset, 78.9 (42.0; 4.5, 540.0) months at presentation and 113.8 (60.0; 7.0, 540.0) months at diagnosis.
Orthopedic surgeons and pediatricians were most frequently consulted pre-diagnosis while clinical geneticists/
metabolic specialists most frequently made the diagnosis. Delayed diagnoses were due to atypical symptoms for 5
patients (28%), while 4 patients (22%) experienced each of subtle symptoms, symptoms commonly associated with
other diseases, or false-negative urine glycosaminoglycan analysis. Two patients (11%) each experienced overgrowth
within the first year of life. Two patients with Morquio A syndrome (11%) were diagnosed with craniosynostosis and
1 (6%) for each of Legg-Calv?-Perthes disease, Leri-Weill syndrome, and pseudoachondroplasia. Early radiographic
features of Morquio A syndrome led to more efficient diagnosis.
Conclusions: Increased awareness of clinical symptomology overlapping with Morquio A syndrome is essential.
Clinicians encountering patients with certain skeletal dysplasia should consider Morquio A syndrome in their
differential diagnosis. Atypical or subtle symptoms should not eliminate Morquio A syndrome from the differential
diagnosis, especially for patients who may have non-classical phenotype of Morquio A syndrome.
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Morquio syndrome (mucopolysaccharidosis IV, MPS
IV) is a rare autosomal recessive lysosomal storage
disease that includes Morquio A and Morquio B [1].
Morquio A is characterized by a deficiency of the en-
zyme N-acetylgalactosamine-6-sulfatase (GALNS) while
Morquio B is a distinct disease characterized by a defi-
ciency of beta-galactosidase (GLB1). The reduced GALNS
activity of Morquio A results in impaired catabolism of* Correspondence: zsplin14@gmail.com
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unless otherwise stated.the glycosaminoglycans (GAGs) keratan sulfate (KS) and
chondroitin-6-sulfate (CS) in various tissues and organs
[2,3], and leads to the multi-systemic manifestations of the
disease. Common initial skeletal symptoms of Morquio A
include short stature [4,5] and dysostosis multiplex [6]
with abnormal gait, genu valgum, pectus carinatum and
kyphoscoliosis [7,8]. Kyphosis and pectus carinatum are
often present before the first year with gibbus observ-
able before the age of two years in patients with a clas-
sical phenotype [9]. In contrast to the joint stiffness
observed in other MPS subtypes, joints in Morquio A
are typically hypermobile secondary to ligamentous laxity
[10]. Mobility is frequently impaired for Morquio Atral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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life (QOL) outcomes [5]. The cardiovascular, respiratory,
auditory, and visual systems are also frequently affected in
patients with Morquio A [8,11,12]. Although intelligence
and the central nervous system remain primarily un-
affected, patients with Morquio A are at significant risk
for atlantoaxial subluxation and spinal cord compression
[8,11,13,14]. Early surgical intervention is often required
to mitigate these risks and hence, accurate early identifica-
tion is imperative [13]. However, with over 220 mutations
identified in the gene encoding GALNS [15], phenotypic
heterogeneity makes Morquio A difficult to identify early
in the disease progression and, for those with a non-
classical form of the disease, erroneous diagnostic labels
may lead to an inaccurate or delayed diagnosis [8-13].
Morquio A syndrome is a progressive disease that may
ultimately result in life-threatening complications for all
patients, not just those with a classical phenotype [13].
As enzyme replacement therapy (ERT) is now available
for patients with Morquio A syndrome, early recognition
of the clinical signs and efficient diagnosis for all pa-
tients with Morquio A becomes even more imperative
to facilitate prompt treatment and prevention of the dev-
astating clinical sequelae of the disease [11,13,14]. To
this end, a group of experts experienced in diagnosing
or managing individuals with Morquio A from major in-
stitutions in the Asia Pacific region recently gathered to
discuss the diagnostic challenges they have encountered,
determine common and unique clinical manifestations
within their cohort of patients, and elucidate any poten-
tial solutions to those challenges encountered during the
diagnostic process of Morquio A.
Methods
A group of multidisciplinary healthcare professionals
(HCPs), including geneticists, metabolic specialists, pedia-
tricians, radiologists, orthopedic surgeons, and cardiolo-
gists, currently or previously involved in diagnosing or
managing individuals with MPS from the Asia Pacific re-
gion gathered for a two-day workshop in Hong Kong in
September, 2013 to discuss the referral and diagnostic
process for Morquio A at their institutions. Prior to the
meeting, each HCP reviewed the medical history of some
cases of Morquio A syndrome at their institution. The
diagnosis was considered challenging if there were subtle
or atypical presenting symptoms, a misdiagnosis prior to
confirmed diagnosis of Morquio A, delays to diagnosis, or
normal or only marginally elevated urine GAG (uGAG)
results. Cases that were identified as having encountered
challenges to the diagnostic process were included in the
analysis. Approval from Institutional Review Boards was
not required as no experimentation was undertaken.
Written patient consent was obtained from all patients
whose case or images were presented.Medical records were reviewed, with a focus on pre-
senting signs and symptoms that led to the diagnosis of
Morquio A. Clinical and laboratory information such as
uGAG analysis, phenotype, disease progression, compli-
cations, and disease burden were included for analysis.
Data was amalgamated and analyzed to identify patterns
in symptomatology. The diagnostic processes, referrals,
and time to diagnosis were analyzed to determine the ef-
fectiveness of certain processes. Awareness of Morquio
A among certain specialists, and symptomatology, which
may be associated with a delay in diagnosis or misdiag-
nosis, were also analyzed. All challenges encountered
were assessed by the authors, who then provided recom-
mendations on how to address similar issues in the diag-
nostic process of Morquio A.
Results
The details of diagnostic processes for 18 patients (77%
female) with Morquio A syndrome presented at the 16
participating institutions in the Asia Pacific region were
available for analysis. The mean (median; min, max) age
at symptom onset was 77.1 (42.0; 0.0, 540.0) months for
all patients and 53.0 (42.0; 3.0, 192.0) months when re-
moving the outliers. Outliers included one infant who
presented at birth with classical symptoms of Morquio
A and was diagnosed within the first year of life and one
patient with non-classical phenotype who was not diag-
nosed until his mid-forties. Although patients presented
to physicians at a mean age (median; min, max) of 78.9
(42.0; 4.5, 540.0) months for all patients and 54.8 (42.0;
12.0, 192.0) months for patients when removing the out-
liers, the mean age (median; min, max) at diagnosis was
113.8 (60.0; 7.0, 540.0) months for all patients and 93.9
(60.0; 14.0, 324.0) months when outliers are removed.
This delay in diagnosis between age at presentation and
age at diagnosis in our cohort was attributed to the atyp-
ical symptoms experienced by 5 patients (28%), 4 pa-
tients (22%) experiencing subtle symptoms, and 4 (22%)
patients with symptoms most commonly associated with
other diseases. Four patients (22%) also had uGAG levels
that did not surpass >5 mg/mmol creatinine to indicate
a positive screening result for Morquio A, but were later
diagnosed by enzyme measurement or molecular ana-
lysis with known pathological mutations being identified.
One of these patients, who had been diagnosed through
radiologic evidence of the disease, had normal urine
electrophoresis even though it was repeated three times
and in two different laboratories (Table 1).
Mutational analysis was available for five patients (27.7%),
all of whom were Australian. One patient, who presented
at 3 months of age, was diagnosed at 12 months of age with
urine KS (uKS) levels of 43.9 (reference range 5.7 ? 31.4)
mg/mmol creatinine and an N-acetylgalactosamine-6-
sulfatase activity of 0.8 (reference range 39 ? 166)
Table 1 Demographics and the pre-diagnostic data from
the medical chart review of patients diagnosed with
Morquio A syndrome
Information from medical charts
Age at symptom onset mean (median; min, max) months
All n =18 77.1 (42.0; 0, 540)
Without outlier n =16 53.0 (42.0; 3.0, 192.0)
Age at first consultation mean (median; min,
max) months
All n =18 78.9 (42.0; 4.5, 540.0)
Without outlier n =16 54.8 (42.0; 12.0, 192.0)
Age at diagnosis mean (median; min, max) months
All n =18 113.8 (60.0; 7.0, 540.0)
Without outlier n =16 93.9 (60.0; 14.0, 324.0)
Diagnoses identified for study inclusion N (%)
Australia 7 (39%)








Pre-diagnostic key symptoms and findings N (%)
Short stature 13 (72%)
Pectus carinatum 9 (50%)
Genu valgum 8 (44%)
Spinal abnormalities 7 (39%)
Gibbus/kyphosis 5 (28%)
Scoliosis 3 (17%)
Atlantoaxial instability 3 (17%)
Hip dysplasia 4 (22%)
Impacted joint range of motion 2 (11%)
Joint pain 2 (11%)
Advanced bone age 2 (11%)
Dermal melanocytosis 2 (11%)
Spinal cord compression 2 (11%)
Overgrowth within one year of age (? big baby? ) 2 (11%)
? Other skeletal abnormalities experienced by patients included
arachnodactyly shortened distal phalanges, dysplastic and fragmented
proximal femoral epiphysis, flattening of femoral heads, acetabular
irregularities, joint space narrowing
? Other general symptoms experienced by patients included upper
respiratory infections, hernia repair, unsettled behavior
Impediments to diagnosis N (%)
Atypical symptoms 5 (28%)
Subtle symptoms 4 (22%)
Table 1 Demographics and the pre-diagnostic data from
the medical chart review of patients diagnosed with
Morquio A syndrome (Continued)
Symptoms associated with other diseases 4 (22%)
Marginally elevated or normal uGAG levels 4 (22%)




Misdiagnosis and other clinical diagnoses
prior to Morquio A diagnosis
N (%)




Advanced bone/dental age 2 (11%)
Overgrowth 2 (11%)
Genu valgum 2 (11%)
Corneal opacity 2 (11%)
Cardiac conduction abnormality 2 (11%)
Legg-Calv?-Perthes Disease 1 (6%)
Leri-Weill syndrome 1 (6%)
Marfan syndrome 1 (6%)
Sotos syndrome 1 (6%)
Pseudoachondroplasia 1 (6%)
Truncal hypotonia 1 (6%)
Hypertolorism 1 (6%)
Splenomegaly 1 (6%)
Growth hormone deficiency 1 (6%)
Torticollis 1 (6%)
Sleep obstruction (snoring) 1 (6%)
Cervical lymphadenopathy 1 (6%)
Apnea/hypopnoea 1 (6%)
Rheumatoid arthritis 1 (6%)
Harrison sulcus 1 (6%)
Lumbar lordosis 1 (6%)
Reversed Madelung deformity 1 (6%)
Autism 1 (6%)





Symptoms are listed separately if experienced by ≥2 patient with confirmed
Morquio A syndrome. Any symptom experienced by <2 patients is combined
in ? Other. ?
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mutations: p.G247D (c.740G >A), p.W326S (c.977G >C),
and p.T313A (c.937A >G). The p.G247D mutation has
been associated with a severe phenotype [16]; however,
neither p.W326S nor p.T313A has been reported previ-
ously. Male twins diagnosed at 4.4 years of age due to one
twin presenting with cord compression at 17 months of age
both had uKS levels of 37.5 (reference range <27.6) g/mol
creatinine and N-acetylgalactosamine-6-sulfatase activities
of 1.3 and 1.4 (reference range 39 ? 166) pmol/min/mg
protein. Both twins are heterozygous for both p.G301C
(c.901G >T), associated with a severe phenotype [16] and
p.H166-Q (c. 498 C >G), also associated with a severe
phenotype [17]. Another male, who is currently six years of
age with a uKS level of 14.8 (reference range <11.9) g/mol
Cr and an N-acetylgalactosamine-6-sulfatase activity of 2.9
(reference range 39 ? 166) pmol/min/mg protein, is homo-
zygous for the p.M41L (c.121A >T) mutation, which is as-
sociated with a milder phenotype [18]. A female patient
with a uKS level of 13.4 (reference range <11.9) mg/mmol
creatinine and an N-acetylgalactosamine-6-sulfatase activity
of 1.4 (reference range 39 ? 166) pmol/min/mg protein is
heterozygous for both the p.I113F (c.337A >T) mutation,
which is associated with a severe phenotype [19], and
the c.244 + 3A > G mutation, which although not previ-
ously reported, is predicted by bioinformatic analysis
software to decrease the efficiency of intron splicing.
This patient presented with delayed walking and fine
motor skills at approximately 1.5 to 2 years of age, with
diagnosis at 4.5 years of age.
Complete information about pre-diagnostic referrals
was not available, although patients were commonly re-
ferred to pediatricians, geneticists, and orthopedic sur-
geons. Clinical geneticists/metabolic specialists most
frequently made the diagnosis of Morquio A (Table 1).
Patients presented with a wide variety and spectrum of
symptoms (Table 1). Symptoms not commonly associ-
ated with Morquio A that occurred in 2 (11%) patients
in this cohort were overgrowth in the first year of age
and extensive dermal melanocytosis (colloquially re-
ferred to as Mongolian blue spots) (Table 1). Both pa-
tients with overgrowth were diagnosed in their early
years (Figure 1) including 1 patient from Australia diag-
nosed at 12 months based on radiographic evidence and
elevated uGAG levels despite being >95th percentile for
length, weight and head circumference. Another patient
from Japan, also classified as experiencing overgrowth
within the first year of life, was diagnosed at 3.3 years
with the clinical suspicion based on other physical fea-
tures associated with Morquio A.
Of the 11 patients (61%) misdiagnosed in our cohort,
the most common misdiagnosis was spondyloepiphyseal
dysplasia (SED) and gibbus/kyphosis, both experienced by
5 patients (28%). Three (17%) patients were diagnosedwith scoliosis and two patients (11%) were diagnosed with
each of craniosynostosis, advanced bone/dental age, over-
growth, genu valgum, corneal opacity and conduction ab-
normalities (Table 1).
Patients presenting with early radiographic features
typical of Morquio A were often diagnosed more effi-
ciently than patients who did not have these common
skeletal findings as initial symptoms. Six patients (33%)
had initial presentation with common skeletal findings
associated with Morquio A syndrome. Of these 6 pa-
tients, 5 presented with short stature, 2 with genu val-
gum, and 2 with other skeletal abnormalities. Five of the
6 patients were diagnosed promptly upon presentation
of the skeletal symptoms.
Discussion
The approval of ERT for Morquio A syndrome makes
the early recognition and diagnosis of Morquio A syn-
drome even more imperative as early treatment initi-
ation will lead to improved patient health and QOL
outcomes. However, obtaining an early diagnosis can be
challenging. In our cohort, mean time of diagnosis was
delayed by 34.9 months or approximately 2.9 years after
first consultation. When removing two outliers from the
cohort, the mean age at presentation is approximately
4.5 years with diagnosis delayed until almost 8 years of
age, representing a significant lapse between presenta-
tion and diagnosis. As expected, it is often those patients
who are experiencing the more common symptoms as-
sociated with the more severe forms of Morquio A syn-
drome that are diagnosed efficiently. However, based on
the limited mutational information from our cohort,
even patients who present with common symptoms of
Morquio A syndrome who are later identified to have
mutations associated with severe phenotype may experi-
ence a delay to diagnosis, possibly due to confounding
symptoms or lack of clinical suspicion. The symptoms
and the diagnostic processes experienced by our cohort
provide insights to commonly encountered barriers to
the diagnosis of Morquio A syndrome. Knowledge of
these barriers may increase the index of clinical suspi-
cion amongst clinicians and therefore expedite the diag-
nostic process.
Raising clinical suspicion of Morquio A amongst clini-
cians frequently encountering these patients in the pre-
diagnostic stage is necessary to ensure early diagnosis
and treatment. However, sparse data exist on the natural
history of Morquio A, especially in early childhood. Skel-
etal symptoms such as joint laxity, gibbus, cervical spine
stenosis and/or cord compression, kyphoscoliosis, pectus
carinatum, bilateral hip dysplasia, progressive genu val-
gum and short stature of unknown etiology should raise
suspicion of Morquio A. This is especially true when in
combination with some accompanying signs and symptoms
Figure 1 Growth charts for a Japanese patient (a) and an Australian patient (b) diagnosed with Morquio A syndrome despite experiencing
overgrowth in their early years.
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ual acuity, hearing impairment, recurrent middle ear infec-
tions, recurrent respiratory tract infection, valvular heart
disease, rhythm abnormalities due to conduction defects,
and recurrent inguinal or umbilical hernia [7,8,11,13]. How-
ever, five (28%) of the patients in our cohort experienced
presenting signs and symptoms that were not previously re-
ported as typical of Morquio A and may provide additional
clues to consider during the clinical diagnosis (Table 1).
Two (11%) patients in this cohort were large for age at
birth. They continued to experience overgrowth in in-
fancy yet were diagnosed with Morquio A in childhood
despite this atypical symptom. Although overgrowth has
been reported in Morquio A syndrome patients [9],clinicians may associate Morquio A with reports describ-
ing growth in infancy as normal at birth but slowing in
early childhood [7,13]. One patient with early over-
growth was initially assessed for congenital adrenal
hyperplasia, Beckwith-Wiedemann and Sotos syndromes
before diagnosis of Morquio A. Extensive dermal mela-
nocytosis, which has previously been reported with MPS
I and II [20-22], was found in several patients in this co-
hort (Table 1). Incomplete data from the remainder of
our cohort limit conclusions regarding the frequency of
overgrowth or extensive dermal melanocytosis in early
childhood by patients with Morquio A and, therefore, the
exact association or significance between these symptoms
and Morquio A remains unclear. These findings may
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that atypical symptoms should not exclude Morquio A
from the differential diagnosis.
Clinical suspicion of Morquio A is typically based on
clinical presentation and interpretation of skeletal radio-
graphs. Signs and symptoms more commonly attributed
to other skeletal disorders, which may also be more famil-
iar to most orthopedic surgeons and radiologists, may re-
sult in misdiagnoses. In our cohort, 9 patients (50%) were
initially diagnosed as SED and Legg-Calv?-Perthes disease
(LCPD), yet the similarities between SED, LCPD and
Morquio A did not prompt the specialists to further ex-
plore other possible contributory diagnoses. This finding
is aligned with published reports, in which patients with
Morquio A have been misdiagnosed with SED [23,24] and
LCPD [23] based on radiographic interpretation [23,24].
The bone abnormalities, short stature and neck associ-
ated with SED, and the chronic pain and progressive de-
terioration of the femoral heads seen with LCPD are
also commonly experienced by individuals with Morquio
A. However, manifestations commonly associated with
and unique to typical Morquio A such as genu valgum
and joint laxity [13] may quickly distinguish these pa-
tients from those with SED or LCPD.
Diagnosis of SED based solely on the presence of scoli-
osis, kyphosis, and/or a single superior notched vertebra
without the presence of either platyspondyly or super-
ior/inferior humping of vertebral bodies is not consistent
with any known form of SED [24] and consideration of
an alternative diagnosis such as Morquio A is prudent.Figure 2 When the mutation study for a six-year-old girl with genu v
indicating pseudoachondroplasia, the patient was referred to an orth
dysosotosis multiplex and Morquio A subsequently confirmed throug
flared iliac wings with deficient ossification of the supra-acetabular portion
her age; femoral capital epiphyses show slight flattening but not significan
valga; mild metaphyseal flaring is present in the distal femora but the dista
mild flattening. c) Lateral spine of the thoracolumbar vertebrae shows rem
with proximal conical shape that centrally converges; phalanges are short b
irregular; distal ulnar is short and growth plate is inclined toward the radiuAlthough patients of non-classical phenotype may not
have the typical, pronounced manifestations that would
lead to a clinical suspicion of a MPS disease [23-25],
awareness of the unique and distinguishing features of
orthopedic diseases may contribute to earlier diagnosis
of Morquio A. There are subtle radiographic differences
between Morquio A (Figure 2a-d) and other skeletal dys-
plasia, such as pseudoachondroplasia (Figure 3a-d) and
SED (image not shown), which could help clinicians dis-
tinguish between these diagnoses. The pelvis and knee
changes observed in patients with Morquio A (Figures 2a
and 2b) differ from those with pseudoachondroplasia
(Figures 3a and 3b). The spine of a patient with pseu-
doachondroplasia (Figure 3c) shows mild platyspondyly
and considerable irregularity of the upper and lower
endplates of the vertebral bodies. The anterior protru-
sion of the central aspects of the vertebral bodies may
mimic to the middle beaking in Morquio A (Figure 2c),
but this mid-central tongue in pseudoachondroplasia is
associated with apophyseal dysplasia of the vertebral
bodies along the upper and lower endplates, resulting in
biconvex configuration (Figure 3c).
Subtle radiographic distinctions also exist between
Morquio A and other MPS subtypes (Figures 4a-c, 5a-c).
While the pelvis of a patient with Morquio A would
have a steep acetabulum with tapering ilium distally with
capital femoral epiphyseal dysplasia (Figure 4a), a patient
of approximately the same age with Hurler syndrome
(MPS IH) would have similar appearances but without
dysplastic capital femoral epiphyses (Figure 5a). Patientsalgum and short stature revealed no COMP gene mutation
opedic clinic with resulting skeletal survey suggestive of
h enzyme analysis (a-d). a) The frog leg position of pelvis shows
and tapering ilium distally; ischium and pubic bones are thickened for
t dysplasia. b) Lower extremity radiograph reveals coxa valga and genu
l femoral epiphyses are normal; the proximal tibial epiphyses show
arkable platyspondyly with middle beaking. d) Metacarpals are short
ut the diaphyseal constriction is preserved; carpal bones are small and
s; radial metaphysis is wide and irregular.
Figure 3 Pseudoachondroplasia in a four-year-old boy, who presented with genu vara and short stature (a-d). a) Pelvis shows small and
round capital femoral epiphyses with an underdeveloped and irregularly shaped lower portion of the ilium that results in horizontal appearance
of the acetabular roofs. b) The lower extremity radiograph shows genu vara with wide and strikingly irregular distal femoral metaphases;
epiphyses at the knees that are dysplastic and triangular in shape in the femoral ends that partly invaginated into the cupping of the femoral
metaphases; dysplastic metaphyseal change is also noted in the distal tibiae. c) The spine radiograph shows mild platyspondyly and considerable
irregularity of the upper and lower endplates of the vertebral bodies; mid-central tongue in pseudoachondroplasia associated with apophyseal
dysplasia of the vertebral bodies along the upper and lower endplates, resulting in biconvex configuration. d) Short metacarpals with
metaphyseal cupping and irregularity and small, round epiphyses; short and stubby phalangeal bones with mild metaphyseal cupping; delayed
ossification of the small and irregular carpal bones with apparent metaphyseal widening and irregularity at the distal radius and ulna.
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or L2 vertebral body, dorsal gibbus, and posterior scal-
loping of the vertebral bodies of the lumbar spine, yet
do not have short vertebral bodies (Figure 5b), in con-
trast to a patient with Morquio A whose lateral thoracol-
umbar spine shows uniform platyspondyly with mild
beaking (Figure 4b). While the phalanges of a patient with
Morquio A retain its diaphyseal constriction (Figure 4c),
there is diaphyseal widening through the phalanges and
metacarpals for patients with Hurler syndrome (Figure 5c).
As well, the joint hypermobility commonly associated with
Morquio syndrome in the early stages may distinguishFigure 4 Radiographic evidence of Morquio A syndrome in a three-ye
(a) shows steep acetabulum with tapering ilium distally. Capital femoral ep
spine (b) shows uniform platyspondly with mild middle beaking. The imag
coning and convergence toward centrally and phalanges that retain diaph
towards each other.patients with Morquio A patients when compared with
the fixed or constricted joint seen in other MPS disorders.
Both lead to functional impairment but in the former, ad-
aptations to hand function, in particular, address passive
hypermobility at the wrist and decreased strength. In the
latter the interventions increase range of movement [26].
This distinction is important in order to correctly manage
the identified problems. In Morquio, the pathophysiology
of this difference could be related to impaired chondro-
cyte function leading to defective growth plate architec-
ture. Whilst some chondrocyte and collagen dysfunction
has been noted in post-mortem studies of adults,ar-old female Morquio A patient (a-c). The pelvic radiograph
iphyseal dysplasia is noted. The lateral image of the thoracolumbar
e of the hand (c) shows strikingly short metacarpals with proximal
yseal constriction. The distal radius and ulna inclined on their planes
Figure 5 Radiographs of a two-year-old female patient diagnosed with Hurler syndrome (MPS IH) (a-c). a) Flaring iliac wings with distal
tapering; capital femoral epiphyses are not dysplastic. b) Hypoplastic L2 vertebral body with dorsal gibbus maximized at this point; inferior
beaking (hook shape) throughout the lumbar vertebral bodies; posterior scalloping of the vertebral bodies in the lumbar spine. c) Short
metacarpals with tapering and converging of proximal ends; diaphyseal widening through the metacarpals and phalanges; distal radius and ulnar
are inclined on their planes towards each other.
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spective study has yet taken place of the children as
they acquire these difficulties [27,28].
Laboratory challenges may further complicate the diag-
nostic process for Morquio syndrome, as with all MPS
disorders. However, the laboratory testing for Morquio A
is more challenging than in the other MPS disorders and
may lead to false-negative results in the early onset form
and especially in the non-classical phenotype [10]. Quanti-
tative analysis of total uGAG is routinely performed as the
first stage of laboratory testing when an MPS disorder is
suspected. Many laboratories only perform further testing
on patients with elevated uGAG levels [10]. Further, quali-
tative uGAG analysis, either by thin layer chromatography
or electrophoresis [29,30] can also prove problematic, with
KS being the most difficult GAG to separate and visualize
[10]. Although using both quantitative and qualitative
uGAG assessments may reduce the potential for false-
negative results, these can still occur, particularly in dilute
urine samples with a very low creatinine concentration. It
is also recognized that patients with non-classical pheno-
type may not have elevated uKS levels [10], and that KS
excretion in the urine decreases with age for patients with
Morquio syndrome [31].
With such a large percentage of patients experiencing
delays to accurate diagnosis of Morquio A syndrome due
to confounding symptoms and other clinical diagnoses in
our cohort, we recommend the use of an algorithm that
includes both presenting manifestations and alternate
clinical diagnoses to assist clinicians who may encounter
patients with Morquio A syndrome. Awareness of clinical
diagnoses that are commonly made for patients who are
later diagnosed with Morquio A syndrome is imperative
to streamline the diagnostic process for these patients.
Based on our cohort, this is especially important when a
patient is clinically diagnosed with atypical or unclassifiedSED, or LCPD. Testing for these patients should include
quantitative and qualitative uGAG analysis and enzymatic
activity in leukocytes or fibroblasts. Due to the high po-
tential for false-negative uGAG analysis, confirmatory
testing should be explored even if the uGAG analysis is
negative for Morquio A syndrome when a high degree of
clinical suspicion remains (Figure 6).
Mutational analysis may assist in obtaining a conclusive
diagnosis, particularly in those with a known family history
of Morquio A syndrome. When using molecular testing for
diagnosis, two known or probable causative mutations on
separate alleles need to be identified, which is not always
possible. In this cohort alone, 4 (21.0%) patients had only
marginally elevated or normal uGAG results and one early
onset patient had a normal electrophoresis pattern. One pa-
tient from Japan presented at 12 years with short stature
and bone deformities. An orthopedic surgeon suspected
SED or Morquio A based on radiographs, short stature,
and pectus carinatum, despite no evidence of genu valgum
or joint laxity, and referred to a pediatrician who
performed the uGAG analysis which resulted in a false-
negative result. Had the pediatrician not pursued enzymatic
analysis due to high levels of clinical suspicion, this patient
who was subsequently confirmed to have Morquio A, may
have been erroneously treated for SED. Conversely, a South
Korean patient in our cohort was initially diagnosed with
LCPD at 11 years of age. Despite negative mutational
analysis of COL2A1 for SED, the diagnosis was revised to
SED at 12 years by a radiologist with a great deal of experi-
ence with Morquio A based on clinical progression of mild
scoliosis, radiographic interpretation of mild platyspondyly,
and the absence of the classic features of Morquio A. It was
not until whole exome sequencing was carried out that the
patient was diagnosed with Morquio A at 27 years of
age [18]. Subsequent qualitative and quantitative uGAG
analysis and retrospective enzyme analysis were consistent
Figure 6 Algorithm for raising clinical suspicion to support an efficient management process for patients with Morquio A syndrome.
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http://www.ojrd.com/content/9/1/192with the disease. If enzyme analysis had been performed
earlier as a means to exclude Morquio A, costly tests such
as whole exome sequencing, erroneous medical surveillance
strategies, and incorrect genetic counseling of the family
may have been avoided.
One critical way to improve early diagnosis of Morquio
A is through continuing medical education activities
such as grand rounds and case sharing or outreach pro-
grams such as consultancy with experienced specialists.
One-on-one outreach programs to departments that are
likely to encounter patients with Morquio A in the
critical pre-diagnostic stage could increase the likelihood
of developing clinical suspicion among these specialties.
Developing a local or regional disease registry of individ-
uals diagnosed for Morquio A syndrome could also
further contribute to the awareness of common and
atypical symptoms, improving the current understanding
of the disease.
Clinicians should be made aware that cultural barriers
such as denial of disease and lack of awareness amongst
patients or their families could result in reluctance to
seek medical attention or under-emphasis of some subtle
symptoms for those with Morquio A in some Asia Pa-
cific countries. Emphasis should be made on presentingsymptoms and radiologic features associated with non-
classical phenotype to ensure efficient diagnosis for all
patients, not just those most severely affected who are
already likely to be diagnosed in a timely manner due to
the significant impact of the disease early in life. It is
also important to educate healthcare professionals of the
significant risks associated with Morquio A syndrome,
such as atlantoaxial instability and cervical cord com-
pression. These complications pose a serious medical
concern for all patients with Morquio A syndrome, espe-
cially those not yet diagnosed, potentially exposing these
patients to a significant risk of anesthetic and periopera-
tive complications [32].
Conclusion
Institutions throughout the Asia Pacific region encoun-
tered patients with Morquio A syndrome prior to diagno-
sis and are experiencing similar challenges as in other
regions, as well as some cultural barriers such as reluc-
tance to seek medical attention in certain regions of Asia
Pacific. Awareness of the disease with attendant clinical
features in multiple specialties through outreach programs
are imperative to ensure that all signs and symptoms
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ally associated with the classical phenotype.
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